Lisinopril use in diabetic patients
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril for Diabetic Patients: Mortality, Blood Pressure, and Kidney Protection
Lisinopril and Mortality in Diabetic Patients with Acute Myocardial Infarction
Lisinopril, an ACE inhibitor, has been shown to significantly reduce short-term mortality in diabetic patients who experience an acute myocardial infarction (MI). When started within 24 hours of MI onset, lisinopril lowered 6-week mortality rates in diabetics more than in non-diabetics, and this benefit was largely maintained at 6 months, even after stopping the drug at 6 weeks. This supports early and widespread use of ACE inhibitors like lisinopril in diabetic patients with acute MI to improve survival outcomes 16.
Blood Pressure Regulation in Diabetic Hypertensive Patients
Lisinopril is effective in lowering both systolic and diastolic blood pressure in patients with diabetes and hypertension. Studies show that after three months of therapy, a significant proportion of patients achieved well-regulated blood pressure, and early response to treatment (within the first month) predicted better long-term control. The effectiveness of lisinopril was consistent regardless of age, gender, BMI, or smoking status . High-dose lisinopril (40 mg daily) was as effective as a combination of lower-dose lisinopril and candesartan in reducing systolic blood pressure, with both regimens being well tolerated .
Renal Protection and Diabetic Nephropathy
Lisinopril provides important kidney protection for diabetic patients, especially those with nephropathy. High-dose lisinopril (20 mg daily) was more effective than low-dose (5 mg daily) in reducing microalbuminuria, a marker of kidney damage, over three months. Blood pressure control was also better with higher doses, though urea levels were slightly higher, and creatinine and potassium remained stable . In direct comparison with atenolol, another antihypertensive, lisinopril reduced albuminuria more, even when blood pressure reduction was similar, suggesting a specific renoprotective effect beyond blood pressure control .
In normotensive diabetic patients with early kidney disease (microalbuminuria), lisinopril slowed the progression of renal damage and reduced urinary albumin excretion, with the greatest benefit seen in those with microalbuminuria at baseline. Importantly, lisinopril did not increase the risk of hypoglycemia or worsen metabolic control 810. Combining lisinopril with verapamil, a calcium channel blocker, further improved glycemic control and kidney function, reducing markers of kidney injury and angiogenesis, and was safe and effective for early-stage nephropathy .
Lisinopril and Diabetic Retinopathy
Lisinopril may also help slow the progression of diabetic retinopathy, even in patients without high blood pressure or significant kidney disease. Over two years, patients on lisinopril had a lower risk of retinopathy progression compared to placebo, suggesting a protective effect on the eyes in type 1 diabetes .
Conclusion
Lisinopril is a valuable medication for diabetic patients, offering benefits that include reduced mortality after acute MI, effective blood pressure control, and significant protection against kidney and eye complications. Its use is supported in both hypertensive and normotensive diabetic patients, particularly those with early signs of kidney damage. Higher doses may offer greater benefits for kidney protection, and combination therapy with other agents can further enhance outcomes. Overall, lisinopril is a cornerstone in the management of diabetes-related cardiovascular and renal risks 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic